Although 1 cycle of trastuzumab reduced Ki67 positivity in nearly all tumours, Ki67 levels declined extensively primarily in tumours with a low DNA replication rate, high tyrosine kinase receptor activity, and high expression of extracellular matrix genes. This evidence concerns the gene NTRK1 and neoplasm.